Skip to main content
Top
Published in: Clinical Rheumatology 10/2019

01-10-2019 | Insulins | Original Article

Metabolic syndrome, non-alcoholic fatty liver disease and liver stiffness in psoriatic arthritis and psoriasis patients

Authors: Augusta Ortolan, Mariagrazia Lorenzin, Giulia Tadiotto, Francesco Paolo Russo, Francesca Oliviero, Mara Felicetti, Renata D’Incà, Marta Favero, Stefano Piaserico, Andrea Doria, Roberta Ramonda

Published in: Clinical Rheumatology | Issue 10/2019

Login to get access

Abstract

Objectives

Non-alcoholic fatty liver disease (NAFLD), potentially evolving into liver fibrosis (LF), is frequent in psoriasis (PsO), but data in psoriatic arthritis (PsA) are lacking. Our study aimed to investigate the prevalence of NALFD and LF in PsA/PsO and the contribution of arthritis in their onset.

Method

PsA and PsO patients were consecutively enrolled. Exclusion criteria were liver diseases causing fibrosis (except NAFLD), alcohol ≥ 20 g/day, daily use of non-steroidal anti-inflammatory drugs and current/previous methotrexate use. Clinical history, biochemical and clinimetrical data and insulin-resistance index HOMA (homeostatic model assessment) were assessed. Patients underwent a liver ultrasound to identify steatosis (therefore NAFLD) and transient elastography, to evaluate LF (stiffness≥ 7 kPa = fibrosis). Statistical analysis included basic statistics, logistic and linear regression analyses (to assess the contribution of arthritis to NAFLD and LF grading, respectively) and Spearman’s correlations; p ≤ 0.05 was considered significant.

Results

Seventy-six patients were enrolled (PsA/PsO 43/33). MetS and LF prevalence were similar between PsA and PsO (35% vs 33%, p = 0.88; 31% vs 28%, p = 0.77, respectively). NAFLD was more frequent in PsO (65% vs 35%, p = 0.044). In multivariable models with NAFLD and LF grading as outcomes, arthritis was not a significant predictor, while HOMA was independently associated with both (OR 1.34; 95%CI 1.06, 1.69; beta 0.88; 95%CI 0.54, 1.21, respectively). Female sex was independently associated with LF grading (beta 1.81; 95%CI 0.05, 3.57).

Conclusions

NAFLD was more frequent in PsO, but MetS and LF prevalence were similar in PsA and PsO. Insulin resistance is the main determinant of NAFLD and LF, while additional contribution of arthritis seems small.
Key Points
• The prevalence of metabolic comorbidities, including liver fibrosis, is overall quite similar between psoriatic arthritis and psoriasis.
• NAFLD is more frequently found in psoriasis than psoriatic arthritis.
• The contribution of arthritis in the onset of metabolic comorbidities seems small.
Appendix
Available only for authorised users
Literature
1.
go back to reference Helmick CG, Lee-Han H, Hirsch SC, Baird TL, Bartlett CL (2014) Prevalence of psoriasis among adults in the U.S.: 2003-2006 and 2009-2010 National Health and Nutrition Examination Surveys. Am J Prev Med 47:37–45PubMedPubMedCentralCrossRef Helmick CG, Lee-Han H, Hirsch SC, Baird TL, Bartlett CL (2014) Prevalence of psoriasis among adults in the U.S.: 2003-2006 and 2009-2010 National Health and Nutrition Examination Surveys. Am J Prev Med 47:37–45PubMedPubMedCentralCrossRef
2.
go back to reference Alamanos Y, Voulgari PV, A a D (2008) Incidence and prevalence of psoriatic arthritis: a systematic review. J Rheumatol 35:1354–1358PubMed Alamanos Y, Voulgari PV, A a D (2008) Incidence and prevalence of psoriatic arthritis: a systematic review. J Rheumatol 35:1354–1358PubMed
3.
go back to reference Prey S, Paul C, Bronsard V, Puzenat E, Gourraud PA, Aractingi S, Aubin F, Bagot M, Cribier B, Joly P, Jullien D, Maitre ML, Richard-Lallemand MA, Ortonne JP (2010) Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature. J Eur Acad Dermatology Venereol 24(Suppl 2):31–35CrossRef Prey S, Paul C, Bronsard V, Puzenat E, Gourraud PA, Aractingi S, Aubin F, Bagot M, Cribier B, Joly P, Jullien D, Maitre ML, Richard-Lallemand MA, Ortonne JP (2010) Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature. J Eur Acad Dermatology Venereol 24(Suppl 2):31–35CrossRef
4.
go back to reference Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, Giannetti A, Girolomoni G (2007) Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 157:68–73PubMedCrossRef Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, Giannetti A, Girolomoni G (2007) Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 157:68–73PubMedCrossRef
5.
go back to reference Raychaudhuri SPSK, Chatterjee S, Nguyen C et al (2010) Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord 8:331–334PubMedPubMedCentralCrossRef Raychaudhuri SPSK, Chatterjee S, Nguyen C et al (2010) Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord 8:331–334PubMedPubMedCentralCrossRef
6.
go back to reference Shen J, Shang Q, Li EK, Leung YY, Kun EW, Kwok LW, Li M, Li TK, Zhu TY, Yu CM, Tam LS (2015) Cumulative inflammatory burden is independently associated with increased arterial stiffness in patients with psoriatic arthritis: a prospective study. Arthritis Res Ther 17:75PubMedPubMedCentralCrossRef Shen J, Shang Q, Li EK, Leung YY, Kun EW, Kwok LW, Li M, Li TK, Zhu TY, Yu CM, Tam LS (2015) Cumulative inflammatory burden is independently associated with increased arterial stiffness in patients with psoriatic arthritis: a prospective study. Arthritis Res Ther 17:75PubMedPubMedCentralCrossRef
7.
go back to reference Lin YC, Dalal D, Churton S, Brennan DM, Korman NJ, Kim ESH, Husni ME (2014) Relationship between metabolic syndrome and carotid intima-media thickness: cross-sectional comparison between psoriasis and psoriatic arthritis. Arthritis Care Res (Hoboken) 66:97–103CrossRef Lin YC, Dalal D, Churton S, Brennan DM, Korman NJ, Kim ESH, Husni ME (2014) Relationship between metabolic syndrome and carotid intima-media thickness: cross-sectional comparison between psoriasis and psoriatic arthritis. Arthritis Care Res (Hoboken) 66:97–103CrossRef
8.
go back to reference Farrell GC, Larter CZ (2006) Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43:S99–S112PubMedCrossRef Farrell GC, Larter CZ (2006) Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43:S99–S112PubMedCrossRef
9.
go back to reference Gisondi P, Targher G, Zoppini G, Girolomoni G (2009) Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 51:758–764PubMedCrossRef Gisondi P, Targher G, Zoppini G, Girolomoni G (2009) Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 51:758–764PubMedCrossRef
10.
go back to reference van der Voort EAM, Koehler E, Nijsten T, Stricker B, Hofman A, Janssen H, Schouten J, Wakkee M (2016) Increased prevalence of advanced liver fibrosis in patients with psoriasis: a cross-sectional analysis from the Rotterdam study. Acta Derm Venereol 96:213–217PubMedCrossRef van der Voort EAM, Koehler E, Nijsten T, Stricker B, Hofman A, Janssen H, Schouten J, Wakkee M (2016) Increased prevalence of advanced liver fibrosis in patients with psoriasis: a cross-sectional analysis from the Rotterdam study. Acta Derm Venereol 96:213–217PubMedCrossRef
11.
go back to reference Gisondi P, Barba E, Girolomoni G (2016) Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis. J Eur Acad Dermatol Venereol 30:282–287PubMedCrossRef Gisondi P, Barba E, Girolomoni G (2016) Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis. J Eur Acad Dermatol Venereol 30:282–287PubMedCrossRef
12.
go back to reference Sporea I, Jurchiş A, Şirli R, Bota S, Sendroiu M (2013) Can transient elastography be a reliable method for assessing liver fibrosis in non alcoholic steatohepatitis (NASH)? Med Ultrason 15:106–110PubMedCrossRef Sporea I, Jurchiş A, Şirli R, Bota S, Sendroiu M (2013) Can transient elastography be a reliable method for assessing liver fibrosis in non alcoholic steatohepatitis (NASH)? Med Ultrason 15:106–110PubMedCrossRef
13.
go back to reference Hashemi SA, Alavian SM, Gholami-Fesharaki M (2016) Assessment of transient elastography (FibroScan) for diagnosis of fibrosis in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Casp J Intern Med 7:242–252 Hashemi SA, Alavian SM, Gholami-Fesharaki M (2016) Assessment of transient elastography (FibroScan) for diagnosis of fibrosis in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Casp J Intern Med 7:242–252
14.
go back to reference Candia R, Ruiz A, Torres-Robles R, Chávez-Tapia N, Méndez-Sánchez N, Arrese M (2015) Risk of non-alcoholic fatty liver disease in patients with psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 29:656–662PubMedCrossRef Candia R, Ruiz A, Torres-Robles R, Chávez-Tapia N, Méndez-Sánchez N, Arrese M (2015) Risk of non-alcoholic fatty liver disease in patients with psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 29:656–662PubMedCrossRef
15.
go back to reference Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ, Korver G, Krueger GG, Strober BE, Lebwohl MG, National Psoriasis Foundation. (2008) National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 58:1031–1042 Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ, Korver G, Krueger GG, Strober BE, Lebwohl MG, National Psoriasis Foundation. (2008) National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 58:1031–1042
16.
go back to reference Rodríguez-Zúñiga MJM, García-Perdomo HA (2017) Systematic review and meta-analysis of the association between psoriasis and metabolic syndrome. J Am Acad Dermatol 77:657–666.e8PubMedCrossRef Rodríguez-Zúñiga MJM, García-Perdomo HA (2017) Systematic review and meta-analysis of the association between psoriasis and metabolic syndrome. J Am Acad Dermatol 77:657–666.e8PubMedCrossRef
17.
go back to reference Bostoen J, Van Praet L, Brochez L et al (2014) A cross-sectional study on the prevalence of metabolic syndrome in psoriasis compared to psoriatic arthritis. J Eur Acad Dermatol Venereol 28:507–511PubMedCrossRef Bostoen J, Van Praet L, Brochez L et al (2014) A cross-sectional study on the prevalence of metabolic syndrome in psoriasis compared to psoriatic arthritis. J Eur Acad Dermatol Venereol 28:507–511PubMedCrossRef
18.
go back to reference Husted JA, Thavaneswaran A, Chandran V, Eder L, Rosen CF, Cook RJ, Gladman DD (2011) Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res (Hoboken) 63:1729–1735CrossRef Husted JA, Thavaneswaran A, Chandran V, Eder L, Rosen CF, Cook RJ, Gladman DD (2011) Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res (Hoboken) 63:1729–1735CrossRef
19.
go back to reference Pérez-Plaza A, Carretero G, Ferrandiz C, Vanaclocha F, Gómez-García FJ, Herrera-Ceballos E, de la Cueva-Dobao P, Belinchón I, Sánchez-Carazo JL, Alsina M, López-Estebaranz JL, Ferrán M, Torrado R, Carrascosa JM, Llamas-Velasco M, Rivera R, Jiménez-Puya R, García-Doval I, Descalzo MA, The Biobadaderm Study Group (2017) Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registry. J Eur Acad Dermatology Venereol 31:1021–1028CrossRef Pérez-Plaza A, Carretero G, Ferrandiz C, Vanaclocha F, Gómez-García FJ, Herrera-Ceballos E, de la Cueva-Dobao P, Belinchón I, Sánchez-Carazo JL, Alsina M, López-Estebaranz JL, Ferrán M, Torrado R, Carrascosa JM, Llamas-Velasco M, Rivera R, Jiménez-Puya R, García-Doval I, Descalzo MA, The Biobadaderm Study Group (2017) Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registry. J Eur Acad Dermatology Venereol 31:1021–1028CrossRef
20.
go back to reference Sakkas LI, Bogdanos DP (2017) Are psoriasis and psoriatic arthritis the same disease? The IL-23/IL-17 axis data. Autoimmun Rev 16:10–15PubMedCrossRef Sakkas LI, Bogdanos DP (2017) Are psoriasis and psoriatic arthritis the same disease? The IL-23/IL-17 axis data. Autoimmun Rev 16:10–15PubMedCrossRef
21.
go back to reference Haroon M, Gallagher P, Heffernan E, FitzGerald O (2014) High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease. J Rheumatol 41:1357–1365PubMedCrossRef Haroon M, Gallagher P, Heffernan E, FitzGerald O (2014) High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease. J Rheumatol 41:1357–1365PubMedCrossRef
22.
go back to reference Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, CASPAR Study Group (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665–2673PubMedCrossRef Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, CASPAR Study Group (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665–2673PubMedCrossRef
23.
24.
go back to reference Wallace TM, Levy JC, Matthews DR (2004) Use and abuse of HOMA modeling. Diabetes Care 27:1487–1495CrossRef Wallace TM, Levy JC, Matthews DR (2004) Use and abuse of HOMA modeling. Diabetes Care 27:1487–1495CrossRef
25.
go back to reference Gayoso-Diz P, Otero-González A, Rodriguez-Alvarez MX, Gude F, García F, de Francisco A, Quintela AG (2013) Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study. BMC Endocr Disord 13:47PubMedPubMedCentralCrossRef Gayoso-Diz P, Otero-González A, Rodriguez-Alvarez MX, Gude F, García F, de Francisco A, Quintela AG (2013) Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study. BMC Endocr Disord 13:47PubMedPubMedCentralCrossRef
26.
go back to reference Expert Panel on Detection, Evaluation and T of HBC in A (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285:2486–2497CrossRef Expert Panel on Detection, Evaluation and T of HBC in A (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285:2486–2497CrossRef
27.
go back to reference Torres DM, Williams CD, Harrison SA (2012) Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 10:837–858PubMedCrossRef Torres DM, Williams CD, Harrison SA (2012) Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 10:837–858PubMedCrossRef
28.
go back to reference Prussick RB, Miele L (2018) Nonalcoholic fatty liver disease in patients with psoriasis: a consequence of systemic inflammatory burden? Br J Dermatol 179:16–29PubMedCrossRef Prussick RB, Miele L (2018) Nonalcoholic fatty liver disease in patients with psoriasis: a consequence of systemic inflammatory burden? Br J Dermatol 179:16–29PubMedCrossRef
29.
go back to reference Mantovani A, Gisondi P, Lonardo A, Targher G (2016) Relationship between non-alcoholic fatty liver disease and psoriasis: a novel Hepato-dermal axis? Int J Mol Sci 17PubMedPubMedCentralCrossRef Mantovani A, Gisondi P, Lonardo A, Targher G (2016) Relationship between non-alcoholic fatty liver disease and psoriasis: a novel Hepato-dermal axis? Int J Mol Sci 17PubMedPubMedCentralCrossRef
30.
go back to reference Ogdie A, Grewal SK, Noe MH, Shin DB, Takeshita J, Chiesa Fuxench ZC, Carr RM, Gelfand JM (2018) Risk of incident liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis: a population-based study. J Invest Dermatol 138:760–767PubMedCrossRef Ogdie A, Grewal SK, Noe MH, Shin DB, Takeshita J, Chiesa Fuxench ZC, Carr RM, Gelfand JM (2018) Risk of incident liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis: a population-based study. J Invest Dermatol 138:760–767PubMedCrossRef
31.
go back to reference Eder L, Abji F, Rosen CF, Chandran V, Gladman DD (2017) The association between obesity and clinical features of psoriatic arthritis: a case-control study. J Rheumatol 44:437–443PubMedCrossRef Eder L, Abji F, Rosen CF, Chandran V, Gladman DD (2017) The association between obesity and clinical features of psoriatic arthritis: a case-control study. J Rheumatol 44:437–443PubMedCrossRef
32.
go back to reference Boyer WR, Johnson TM, Fitzhugh EC, Richardson MR, Churilla JR (2016) The associations between increasing degrees of HOMA-IR and measurements of adiposity among Euglycemic U.S. adults. In: Metab Syndr Relat Disord, vol 14, pp 108–113 Boyer WR, Johnson TM, Fitzhugh EC, Richardson MR, Churilla JR (2016) The associations between increasing degrees of HOMA-IR and measurements of adiposity among Euglycemic U.S. adults. In: Metab Syndr Relat Disord, vol 14, pp 108–113
33.
go back to reference Okorodudu DO, Jumean MF, Montori VM, Romero-Corral A, Somers VK, Erwin PJ, Lopez-Jimenez F (2010) Diagnostic performance of body mass index to identify obesity as defined by body adiposity: a systematic review and meta-analysis. Int J Obes 34:791–799CrossRef Okorodudu DO, Jumean MF, Montori VM, Romero-Corral A, Somers VK, Erwin PJ, Lopez-Jimenez F (2010) Diagnostic performance of body mass index to identify obesity as defined by body adiposity: a systematic review and meta-analysis. Int J Obes 34:791–799CrossRef
34.
go back to reference Yilmaz E, Tamer E, Artüz F et al (2017) Evaluation of serum uric acid levels in psoriasis vulgaris. Turkish J Med Sci 47:531–534CrossRef Yilmaz E, Tamer E, Artüz F et al (2017) Evaluation of serum uric acid levels in psoriasis vulgaris. Turkish J Med Sci 47:531–534CrossRef
35.
go back to reference Van Der Voort EAM, Koehler EM, Dowlatshahi EA et al (2014) Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: results from a population-based study. J Am Acad Dermatol 70:517–524PubMedCrossRef Van Der Voort EAM, Koehler EM, Dowlatshahi EA et al (2014) Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: results from a population-based study. J Am Acad Dermatol 70:517–524PubMedCrossRef
36.
go back to reference Abedini R, Salehi M, Lajevardi V, Beygi S (2015) Patients with psoriasis are at a higher risk of developing nonalcoholic fatty liver disease. Clin Exp Dermatol 40:722–727PubMedCrossRef Abedini R, Salehi M, Lajevardi V, Beygi S (2015) Patients with psoriasis are at a higher risk of developing nonalcoholic fatty liver disease. Clin Exp Dermatol 40:722–727PubMedCrossRef
37.
go back to reference Ramonda R, Puato M, Punzi L, Rattazzi M, Zanon M, Balbi G, Ortolan A, Frallonardo P, Faggin E, Plebani M, Zaninotto M, Lorenzin M, Pauletto P, Doria A (2014) Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers: a two-year prospective observational study. Joint Bone Spine 81:421–425PubMedCrossRef Ramonda R, Puato M, Punzi L, Rattazzi M, Zanon M, Balbi G, Ortolan A, Frallonardo P, Faggin E, Plebani M, Zaninotto M, Lorenzin M, Pauletto P, Doria A (2014) Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers: a two-year prospective observational study. Joint Bone Spine 81:421–425PubMedCrossRef
38.
go back to reference Tveit KS, Duvetorp A, Østergaard M, Skov L, Danielsen K, Iversen L, Seifert O (2019) Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP). J Eur Acad Dermatol Venereol 33:340–354PubMedCrossRef Tveit KS, Duvetorp A, Østergaard M, Skov L, Danielsen K, Iversen L, Seifert O (2019) Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP). J Eur Acad Dermatol Venereol 33:340–354PubMedCrossRef
39.
go back to reference Costa L, Caso F, Ramonda R, del Puente A, Cantarini L, Darda MA, Caso P, Lorenzin M, Fiocco U, Punzi L, Scarpa R (2015) Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study. Immunol Res 61:147–153PubMedCrossRef Costa L, Caso F, Ramonda R, del Puente A, Cantarini L, Darda MA, Caso P, Lorenzin M, Fiocco U, Punzi L, Scarpa R (2015) Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study. Immunol Res 61:147–153PubMedCrossRef
40.
go back to reference Coates LC, Gottlieb AB, Merola JF, Boone C, Szumski A, Chhabra A (2019) Comparison of different remission and low disease definitions in psoriatic arthritis and evaluation of their prognostic value. J Rheumatol 46:160–165PubMedCrossRef Coates LC, Gottlieb AB, Merola JF, Boone C, Szumski A, Chhabra A (2019) Comparison of different remission and low disease definitions in psoriatic arthritis and evaluation of their prognostic value. J Rheumatol 46:160–165PubMedCrossRef
41.
go back to reference Coates LC, Kavanaugh A, Mease PJ et al (2016) Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol (Hoboken, NJ 68:1060–1071PubMed Coates LC, Kavanaugh A, Mease PJ et al (2016) Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol (Hoboken, NJ 68:1060–1071PubMed
42.
go back to reference Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, Emery P, Landewé R, Oliver S, Aletaha D, Betteridge N, Braun J, Burmester G, Cañete JD, Damjanov N, FitzGerald O, Haglund E, Helliwell P, Kvien TK, Lories R, Luger T, Maccarone M, Marzo-Ortega H, McGonagle D, McInnes IB, Olivieri I, Pavelka K, Schett G, Sieper J, van den Bosch F, Veale DJ, Wollenhaupt J, Zink A, van der Heijde D (2016) European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 75:499–510PubMedCrossRef Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, Emery P, Landewé R, Oliver S, Aletaha D, Betteridge N, Braun J, Burmester G, Cañete JD, Damjanov N, FitzGerald O, Haglund E, Helliwell P, Kvien TK, Lories R, Luger T, Maccarone M, Marzo-Ortega H, McGonagle D, McInnes IB, Olivieri I, Pavelka K, Schett G, Sieper J, van den Bosch F, Veale DJ, Wollenhaupt J, Zink A, van der Heijde D (2016) European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 75:499–510PubMedCrossRef
Metadata
Title
Metabolic syndrome, non-alcoholic fatty liver disease and liver stiffness in psoriatic arthritis and psoriasis patients
Authors
Augusta Ortolan
Mariagrazia Lorenzin
Giulia Tadiotto
Francesco Paolo Russo
Francesca Oliviero
Mara Felicetti
Renata D’Incà
Marta Favero
Stefano Piaserico
Andrea Doria
Roberta Ramonda
Publication date
01-10-2019
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 10/2019
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-019-04646-7

Other articles of this Issue 10/2019

Clinical Rheumatology 10/2019 Go to the issue

Letters of Biomedical and Clinical Research

Negative specificity for DSF70 in ANA positive leprosy sera

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine